Alemtuzumab slows brain volume loss over 4 years despite most relapsing-remitting multiple sclerosis patients not receiving treatment for 3 years

Authors
Category Primary study
JournalNeurology
Year 2015
This article has no abstract
Epistemonikos ID: 2c369fc01392bc64c11eb4ee073f256ceb03d6fd
First added on: Feb 07, 2025